The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics

Table 3 Number of subjects from different cohorts for each modality by diagnosis

Cohort	Diagnosis	Clinical data	Plasma	DNA	MRI	CSF
Amsterdam	NC	30	29	26	30	30
	MCI	82	80	68	82	82
	AD-type dementia	60	60	53	60	60
Antwerp	MCI	103	100	101	50	103
Antwerp	AD-type dementia	46	47	46	0	46
DESCRIPA	NC	12	12	8	5	12
DESCRIPA	MCI	17	17	12	9	17
EDAR	NC	48	47	42	14	47
	MCI	77	75	65	24	75
	AD-type dementia	79	78	69	19	76
GAP	NC	40	40	40	38	40
Gothenburg	NC	49	48	–	48	–
Gothenburg	MCI	46	44	–	46	–
IDIBAPS	NC	76	77	–	40	–
	MCI	27	27	–	14	–
	AD-type dementia	17	16	–	14	–
Lausanne	NC	12	12	12	12	12
Lausanne	MCI	28	28	28	27	28
Leuven	NC	180	163	168	179	–
PharmaCog	MCI	147	144	146	147	147
Sant Pau	NC	45	45	45	–	–
Total	NC	492	473	341	366	141
	MCI	527	515	420	399	452
	AD-type dementia	202	201	168	100	182
	Overall	1221	1189	929	865	775

CSF cerebrospinal fluid, DESCRIPA development of screening guidelines and clinical criteria for predementia Alzheimer's disease, EDAR beta amyloid oligomers in the early diagnosis of AD and as a marker for treatment reponse, GAP gipuzkoa Alzheimer project, IDIBAPS institut d'investigacions biomèdiques August Pi i Sunyer, MCI mild cognitive impairment, MRI magnetic resonance imaging, NC normal cognition

ISSN: 1758-9193